Have any questions?
+44 1234 567 890
Fix CHAGAS Study Reaches 50% Patient Enrollment
Successful collaboration between the InCor Heart Center and i2medi—the LATAM market access expert.
50% of the planned patients have been successfully enrolled. InCor reports this milestone in the randomized FIX-Chargas study on CCM in patients with Chargas-related heart failure. I2medi initiated the project with InCor and supported the successful enrollment in Braislein—from study management to the expert network.
In this way, i2medi indirectly positions itself as a business development agency and COR partner for medtech companies in Latin America.